|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions decreases expression |
ISO |
ICI 118551 inhibits the reaction [Formoterol Fumarate results in decreased expression of ACTA2 protein] Formoterol Fumarate results in decreased expression of ACTA2 mRNA; Formoterol Fumarate results in decreased expression of ACTA2 protein |
CTD |
PMID:21603974 |
|
NCBI chr 1:252,537,614...252,550,394
Ensembl chr 1:252,537,615...252,550,394
|
|
G |
Adrb1 |
adrenoceptor beta 1 |
multiple interactions |
ISO |
[Formoterol Fumarate binds to and results in increased activity of ADRB1 protein] which results in increased abundance of Cyclic AMP; Formoterol Fumarate binds to and results in increased activity of ADRB1 protein; Formoterol Fumarate inhibits the reaction [cyanopindolol binds to ADRB1 protein] |
CTD |
PMID:14730417 |
|
NCBI chr 1:277,537,585...277,538,985
Ensembl chr 1:277,537,585...277,538,985
|
|
G |
Adrb2 |
adrenoceptor beta 2 |
multiple interactions increases phosphorylation affects expression |
ISO |
[Formoterol Fumarate binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [Formoterol Fumarate binds to and results in increased activity of ADRB2 protein] which results in increased phosphorylation of and results in increased activity of MAPK1 protein; [Formoterol Fumarate binds to and results in increased activity of ADRB2 protein] which results in increased phosphorylation of and results in increased activity of MAPK3 protein; Dactinomycin inhibits the reaction [Formoterol Fumarate affects the expression of ADRB2 mRNA]; Formoterol Fumarate binds to and results in increased activity of ADRB2 protein; Formoterol Fumarate inhibits the reaction [cyanopindolol binds to ADRB2 protein]; Formoterol Fumarate promotes the reaction [Cycloheximide results in increased expression of ADRB2 mRNA]; ICI 118551 inhibits the reaction [Formoterol Fumarate affects the expression of ADRB2 mRNA] Formoterol Fumarate results in increased phosphorylation of ADRB2 protein |
CTD |
PMID:14722251 PMID:14730417 PMID:16980553 PMID:20061444 PMID:24705868 |
|
NCBI chr18:57,513,792...57,515,834
Ensembl chr18:57,513,793...57,515,834
|
|
G |
Adrb3 |
adrenoceptor beta 3 |
multiple interactions |
ISO |
[Formoterol Fumarate binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; Formoterol Fumarate binds to and results in increased activity of ADRB3 protein; Formoterol Fumarate inhibits the reaction [cyanopindolol binds to ADRB3 protein] |
CTD |
PMID:14730417 |
|
NCBI chr16:69,003,541...69,006,632
Ensembl chr16:69,003,868...69,006,632
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression |
ISO |
Formoterol Fumarate results in decreased expression of BCL2 mRNA; Formoterol Fumarate results in decreased expression of BCL2 protein |
CTD |
PMID:14687023 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
multiple interactions |
ISO |
[Beclomethasone co-treated with Formoterol Fumarate] results in decreased secretion of CCL5 protein |
CTD |
PMID:15679717 |
|
NCBI chr10:70,739,764...70,744,303
Ensembl chr10:70,739,800...70,744,315
|
|
G |
Cd44 |
CD44 molecule (Indian blood group) |
multiple interactions |
ISO |
Formoterol Fumarate promotes the reaction [Beclomethasone inhibits the reaction [FGF2 protein results in decreased expression of CD44 protein]]; Formoterol Fumarate promotes the reaction [Beclomethasone inhibits the reaction [IL4 protein results in decreased expression of CD44 protein]] |
CTD |
PMID:18076728 |
|
NCBI chr 3:92,695,083...92,783,820
Ensembl chr 3:92,696,313...92,783,658
|
|
G |
Csf2 |
colony stimulating factor 2 |
multiple interactions |
ISO |
[Beclomethasone co-treated with Formoterol Fumarate] results in decreased secretion of CSF2 protein |
CTD |
PMID:15679717 |
|
NCBI chr10:39,602,089...39,604,070
Ensembl chr10:39,602,089...39,604,070
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
multiple interactions |
ISO |
[Beclomethasone co-treated with Formoterol Fumarate] inhibits the reaction [FGF2 protein results in increased secretion of FN1 protein]; Formoterol Fumarate promotes the reaction [Beclomethasone inhibits the reaction [FGF2 protein results in decreased expression of CD44 protein]]; Formoterol Fumarate promotes the reaction [Beclomethasone inhibits the reaction [FGF2 protein results in decreased expression of THY1 protein]]; Formoterol Fumarate promotes the reaction [Beclomethasone results in decreased activity of FGF2 protein] |
CTD |
PMID:18076728 |
|
NCBI chr 2:124,081,072...124,134,133
Ensembl chr 2:124,081,072...124,134,681
|
|
G |
Fn1 |
fibronectin 1 |
multiple interactions |
ISO |
[Beclomethasone co-treated with Formoterol Fumarate] inhibits the reaction [FGF2 protein results in increased secretion of FN1 protein] |
CTD |
PMID:18076728 |
|
NCBI chr 9:78,900,111...78,969,018
Ensembl chr 9:78,900,103...78,969,078
|
|
G |
Il10 |
interleukin 10 |
decreases expression |
EXP |
Formoterol Fumarate results in decreased expression of IL10 mRNA |
CTD |
PMID:16908771 |
|
NCBI chr13:47,738,933...47,743,392
Ensembl chr13:47,739,526...47,743,392
|
|
G |
Il13 |
interleukin 13 |
multiple interactions |
EXP |
desisobutyrylciclesonide promotes the reaction [Formoterol Fumarate inhibits the reaction [dinitrophenyl-bovine serum albumin results in increased expression of IL13 mRNA]]; Formoterol Fumarate inhibits the reaction [dinitrophenyl-bovine serum albumin results in increased expression of IL13 mRNA]; Formoterol Fumarate inhibits the reaction [dinitrophenyl-bovine serum albumin results in increased expression of IL13 protein] |
CTD |
PMID:26003274 |
|
NCBI chr10:38,982,909...38,985,466
Ensembl chr10:38,982,909...38,985,466
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
[TNF protein co-treated with IL1B protein] results in decreased susceptibility to Formoterol Fumarate; Budesonide inhibits the reaction [[TNF protein co-treated with IL1B protein] results in decreased susceptibility to Formoterol Fumarate] |
CTD |
PMID:20061444 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il4 |
interleukin 4 |
multiple interactions |
EXP ISO |
desisobutyrylciclesonide promotes the reaction [Formoterol Fumarate inhibits the reaction [dinitrophenyl-bovine serum albumin results in increased expression of IL4 mRNA]]; desisobutyrylciclesonide promotes the reaction [Formoterol Fumarate inhibits the reaction [dinitrophenyl-bovine serum albumin results in increased expression of IL4 protein]]; Formoterol Fumarate inhibits the reaction [dinitrophenyl-bovine serum albumin results in increased expression of IL4 mRNA]; Formoterol Fumarate inhibits the reaction [dinitrophenyl-bovine serum albumin results in increased expression of IL4 protein]; Formoterol Fumarate promotes the reaction [desisobutyrylciclesonide inhibits the reaction [dinitrophenyl-bovine serum albumin results in increased expression of IL4 mRNA]] Formoterol Fumarate promotes the reaction [Beclomethasone inhibits the reaction [IL4 protein results in decreased expression of CD44 protein]] |
CTD |
PMID:18076728 PMID:26003274 |
|
NCBI chr10:38,963,979...38,969,531
Ensembl chr10:38,963,979...38,969,531
|
|
G |
Il6 |
interleukin 6 |
affects expression increases expression multiple interactions |
EXP |
Formoterol Fumarate affects the expression of IL6 mRNA; Formoterol Fumarate affects the expression of IL6 protein Formoterol Fumarate results in increased expression of IL6 mRNA Formoterol Fumarate inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein] |
CTD |
PMID:10525314 PMID:11096136 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
decreases activity |
ISO |
Formoterol Fumarate results in decreased activity of KCNH2 protein |
CTD |
PMID:28551711 |
|
NCBI chr 4:7,355,066...7,387,282
Ensembl chr 4:7,355,574...7,387,253
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
[Formoterol Fumarate binds to and results in increased activity of ADRB2 protein] which results in increased phosphorylation of and results in increased activity of MAPK1 protein; Formoterol Fumarate results in increased phosphorylation of and results in increased activity of MAPK1 protein |
CTD |
PMID:15603589 PMID:16980553 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
[Formoterol Fumarate binds to and results in increased activity of ADRB2 protein] which results in increased phosphorylation of and results in increased activity of MAPK3 protein; Formoterol Fumarate results in increased phosphorylation of and results in increased activity of MAPK3 protein |
CTD |
PMID:15603589 PMID:16980553 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
EXP |
[Formoterol Fumarate co-treated with desisobutyrylciclesonide] inhibits the reaction [dinitrophenyl-bovine serum albumin results in increased phosphorylation of MAPK8 protein]; Formoterol Fumarate inhibits the reaction [dinitrophenyl-bovine serum albumin results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:26003274 |
|
NCBI chr16:9,620,854...9,709,342
Ensembl chr16:9,625,177...9,709,347
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
multiple interactions |
EXP |
Formoterol Fumarate inhibits the reaction [dinitrophenyl-bovine serum albumin results in increased phosphorylation of MAPK9 protein] |
CTD |
PMID:26003274 |
|
NCBI chr10:35,333,859...35,374,364
Ensembl chr10:35,333,859...35,374,355
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
EXP |
Budesonide promotes the reaction [Formoterol Fumarate inhibits the reaction [Cadmium Chloride results in increased activity of MMP9 protein]]; Formoterol Fumarate inhibits the reaction [Cadmium Chloride results in increased activity of MMP9 protein]; Formoterol Fumarate promotes the reaction [Budesonide inhibits the reaction [Cadmium Chloride results in increased activity of MMP9 protein]]; Ipratropium promotes the reaction [Formoterol Fumarate inhibits the reaction [Cadmium results in increased activity of MMP9 protein]] |
CTD |
PMID:20826145 PMID:25313925 |
|
NCBI chr 3:161,413,410...161,421,473
Ensembl chr 3:161,413,298...161,421,520
|
|
G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
multiple interactions |
ISO |
[Beclomethasone co-treated with Formoterol Fumarate] affects the localization of NR3C1 protein |
CTD |
PMID:15679717 |
|
NCBI chr18:31,728,373...32,704,022
Ensembl chr18:31,728,373...31,749,647
|
|
G |
Rnase3 |
ribonuclease A family member 3 |
decreases expression |
ISO |
Formoterol Fumarate results in decreased expression of RNASE3 protein |
CTD |
PMID:1443864 |
|
NCBI chr15:28,216,744...28,217,614
Ensembl chr15:28,216,744...28,217,614
|
|
G |
Slc22a3 |
solute carrier family 22 member 3 |
multiple interactions increases uptake |
ISO |
Budesonide inhibits the reaction [SLC22A3 protein results in increased uptake of Formoterol Fumarate]; Corticosterone inhibits the reaction [SLC22A3 protein results in increased uptake of Formoterol Fumarate]; Fluticasone inhibits the reaction [SLC22A3 protein results in increased uptake of Formoterol Fumarate]; SLC22A3 protein results in increased susceptibility to [beclomethasone 17-monopropionate results in decreased transport of Formoterol Fumarate]; SLC22A3 protein results in increased susceptibility to [Budesonide results in decreased transport of Formoterol Fumarate]; SLC22A3 protein results in increased susceptibility to [desisobutyrylciclesonide results in decreased transport of Formoterol Fumarate]; SLC22A3 protein results in increased susceptibility to [Fluticasone results in decreased transport of Formoterol Fumarate] |
CTD |
PMID:17920670 PMID:21914487 |
|
NCBI chr 1:48,433,079...48,521,261
Ensembl chr 1:48,433,079...48,521,256
|
|
G |
Thy1 |
Thy-1 cell surface antigen |
multiple interactions |
ISO |
Formoterol Fumarate promotes the reaction [Beclomethasone inhibits the reaction [FGF2 protein results in decreased expression of THY1 protein]] |
CTD |
PMID:18076728 |
|
NCBI chr 8:48,382,121...48,387,271
Ensembl chr 8:48,382,121...48,386,935
|
|
G |
Tnf |
tumor necrosis factor |
affects expression multiple interactions |
EXP ISO |
Formoterol Fumarate affects the expression of TNF mRNA; Formoterol Fumarate affects the expression of TNF protein Formoterol Fumarate inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; Formoterol Fumarate inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein] [TNF protein co-treated with IL1B protein] results in decreased susceptibility to Formoterol Fumarate; Budesonide inhibits the reaction [[TNF protein co-treated with IL1B protein] results in decreased susceptibility to Formoterol Fumarate] |
CTD |
PMID:10525314 PMID:11096136 PMID:20061444 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|